DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Strength Seen in Oak Street Health, Inc. (OSH): Can Its 29.7% Jump Turn into More Strength?
by Zacks Equity Research
Oak Street Health, Inc. (OSH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
U.S. Physical Therapy (USPH) Soars 3.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
U.S. Physical Therapy (USPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
Is the Options Market Predicting a Spike in DaVita (DVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to DaVita (DVA) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in DaVita (DVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to DaVita (DVA) stock based on the movements in the options market lately.
DaVita (DVA) Q3 Earnings Lag Estimates, 2022 EPS View Cut
by Zacks Equity Research
DaVita's (DVA) Q3 performance gets a boost from strength in both its segments.
DaVita HealthCare (DVA) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.12% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) third quarter's top line.
DaVita HealthCare (DVA) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View
by Zacks Equity Research
DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.
DaVita HealthCare (DVA) Tops Q2 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 9% and 0.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care.
DaVita HealthCare (DVA) Surges 6%: Is This an Indication of Further Gains?
by Zacks Equity Research
DaVita HealthCare (DVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Hold on to DaVita (DVA) Stock For Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
3 Stocks to Watch From a Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.
Medtronic's (MDT) New JV With DaVita to Expand Renal Care Line
by Zacks Equity Research
NewCo is expected to operate successfully, leveraging Medtronic's (MDT) capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider.
Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View
by Zacks Equity Research
Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.97% and 2.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.
LHC Group (LHCG) Ties Up to Improve Home Health Services
by Zacks Equity Research
LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.
Is DaVita (DVA) a Suitable Value Investor Stock Now?
by Zacks Equity Research
Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.
DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.